B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 Clinical Trials

11 clinical trials for B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma — RECRUITING · PHASE2
• Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
• Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia — RECRUITING · PHASE1
• Asciminib as Maintenance Treatment After Cellular Therapies for Adults With Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia — RECRUITING · PHASE1
• Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults — ACTIVE_NOT_RECRUITING · PHASE3
• Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma — ACTIVE_NOT_RECRUITING · PHASE3
• Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia — ACTIVE_NOT_RECRUITING · PHASE1
• Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients With Acute Lymphoblastic Leukemia — ACTIVE_NOT_RECRUITING · PHASE2
• Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia — COMPLETED · PHASE2
• Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML — COMPLETED · PHASE1

Refine this search